Advances in hydrogel technology have unlocked unique and valuable capabilities that are
being applied to a diverse set of translational applications. Hydrogels perform functions …

The stimulator of interferon genes (STING) cellular signaling pathway is a promising target
for cancer immunotherapy. Activation of the intracellular STING protein triggers the …

Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

The often immune-suppressive tumor microenvironment (TME) may hinder immune evasion
and response to checkpoint blockade therapies. Pharmacological activation of the STING …

Radiotherapy (RT) uses ionizing radiation to eradicate localized tumors and, in rare cases,
control tumors outside of the irradiated fields via stimulating an antitumor immune response …

The stimulator of interferon genes (STING) is an endoplasmic reticulum transmembrane
protein that is a target of therapeutics for infectious diseases and cancer. However, early …

Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …

Endogenous cytoplasmic DNA (cytoDNA) species are emerging as key mediators of
inflammation in diverse physiological and pathological contexts. Although the role of …

Among the few available mRNA delivery vehicles, lipid nanoparticles (LNPs) are the most
clinically advanced but they require cumbersome four components and suffer from …

In situ cancer vaccination refers to any approach that exploits tumour antigens available at a
tumour site to induce tumour-specific adaptive immune responses. These approaches hold …